跳至主要内容
临床试验/NCT00914121
NCT00914121已完成1 期

A Single Dose, Crossover, Placebo- and Moxifloxacin- Controlled Study of the Effects of Bosutinib on Cardiac Repolarization in Healthy Adult Subjects

Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点目标入组 60 人开始时间: 2009年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
60
主要终点
Corrected QT interval, including QTcN, QTcB, and QTcF

研究概览

简要总结

The purpose of this study is to examine the effect of SKI-606 on rhythms of the heart (cardiac repolarization)

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Men or women of nonchildbearing potential; 18-50 years old; healthy as determined by the investigator, including physical examination, laboratory test results, and medical history.

排除标准

  • 未提供

研究组 & 干预措施

1

Experimental

SKI-606 alone

干预措施: SKI-606 (Drug)

2

Placebo Comparator

Placebo

干预措施: Placebo (Drug)

3

Active Comparator

Moxifloxacin

干预措施: Moxifloxacin (Drug)

4

Experimental

SKI-606 plus ketoconazole

干预措施: SKI-606 (Drug)

5

Placebo Comparator

Placebo plus ketoconazole

干预措施: Placebo (Drug)

结局指标

主要结局

Corrected QT interval, including QTcN, QTcB, and QTcF

时间窗: 6 weeks

次要结局

  • Laboratory evaluations, Vital Sign measurements, Adverse Event reports(6 weeks)

研究者

发起方
Wyeth is now a wholly owned subsidiary of Pfizer
申办方类型
Industry

相似试验

Study Evaluating The Effect of Bosutinib (SKI-606)... | 临床试验